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LETTERS TO NATURE
o f  105 Balb c/3T3, a-PKC/3T3 or 3T3 containing the pLTR 
expression vector alone did not form tumours even after two 
months (Table 2).
To investigate whether the transforming properties of the 
m utant PKC gene are due to the four point mutations in the 
coding region, we have back-mutated the transforming allele of 
th e  PKC gene. Oligonucleotide-directed mutagenesis was used 
t o  back-mutate the four point mutations in the mutated PKC 
cD N A  and the region of each mutation was sequenced to verify 
th e  alteration. A back-mutated UV25 cDNA (B-UV25) clone 
w as isolated and inserted into the pLTR expression vector, Balb 
c/3T3 cells were co-transfected with the back UV-25 cDNA and 
PSV-Neo plasmids. Transfected cells were selected for G418 
antibiotic-resistance and we isolated one clone expressing the 
back-mutated PKC gene (B-UV25/3T3). The B-UV25/3T3 cell 
line  contains about ten times the level of high-affinity phorbol- 
ester binding sites and its PKC activity is increased tenfod (Table 
1 )» The revertant B-UV25/3T3 cell line, however, does not 
display features typical of malignant transformed cells (such as 
morphology, formation of dense foci and anchorage-indepen- 
dentgrowth) and fails to induce tumours in vivo when inoculated 
into nude mice (Table 2).
Our study establishes that the mutant PKC gene can be 
activated as a potent oncogene when its expression is driven by 
a  strong promoter. Moreover, it is also evident that the mere 
expression, without overexpression, of the mutant a-PK C gene 
is sufficient to fully transform Balb c/3T3 fibroblasts. This 
mutated a-PKC gene differs from the a-, and y-PKC-iso- 
enzymes by four point mutations located in the regulatory and 
the catalytic domains. These results corroborate the findings of 
a  number of distinct activating point mutations in the coding 
regions of the ras> neu and fm s  genes18"20. It may be that a 
subset of proto-oncogenes, including the PKC gene, are acti­
vated after exposure to carcinogens or ultraviolet light, which 
act as point mutagens21. The idea of the PKC gene belonging 
to such a family is strengthened by the finding of a tumour- 
specific microscopic substitution in the a-PK C  gene in a malig­
nant melanoma primary cell line22. Oncogenic conversion of 
PKC may shed light not only on the process of carcinogenesis 
but also on the critical aspects of signal transduction and the 
mitogenic response. □
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Th e  lymphocyte function-associated molecule LFA-1 (CD 11a/ 
CD 18) plays a key part in lymphocyte adhesion1,2. Lympho­
cytes do not adhere spontaneously; activation of protein kinase 
C (PKC)3 by phorbol esters, however, gives rise to strong LFA-1- 
dependent adhesion4, indicating that activation of LFA-1 is 
required to induce cell adhesion. We have now investigated whether 
the functionally important CD2 and CD3 surface structures on T 
lymphocytes5"*8 are involved in the activation of LFA-1. The stimu­
lation of these molecules, which causes activation of PKC9,10, 
strongly promoted LFA-l-dependent adhesion. Furthermore, we 
demonstrate by using cells from an LFA-i-deficient patient that 
this enhanced lymphocyte adhesion is caused by activation of the 
LFA-1 molecule and not by activation of its ligands. LFA-1 was 
persistently activated by triggering through CD2 but only 
transiently by triggering through CD3. We postulate that CD2 
and CD3 can differentially regulate the affinity of LFA-1 for its 
ligands by modulating its molecular conformation through PKC- 
dependent mechanisms.
LFA-1, CR3 and p l5 0 ,95 comprise a group of heterodimeric 
adhesion receptors with a unique a-chain and a common ¡3- 
chain. They mediate adhesion among leukocytes and of
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FIG. 1 Photomicrographs of homotypic cell adhesion and Its inhibition by 
anti-LFA-1 antibodies. JS-136 cells were incubated with: a, NKI-L16 antibody 
(1 fxg ml“ 1); S0% adhesion; b, NKI-L16 ( l jx g m r 1) and anti-LFA-1 
(5 fxg ml"1); <1% adhesion; or c, anti-CD3 (10 p,g ml“ 1; 60% adhesion), and 
scored in the qualitative assay (Table 1) for 40 min.
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TA8LE 1 Homotypic cell adhesion of JS-136 T cells and NL-3 NK cells
JS-136
Aggregation (%)
NL-3
Medium +Anti-LFA-1 +Anti-LFA-3
«
Medium +Anti-LFA-1 +Anti-LFA-3
Medium 10 <1 10 10 <1 10
TPA 60 <1 60 80 <1 80
NKI-L16 80 <1 80 70 <1 70
Anti-CD3 60 <1 60 10 <1 10
Anti-CD2 70 <1 60 60 <1 60
Anti-CD4 10 <1 10 10 <1 10
Antl-CD71 10 <1 10 10 <1 10
Induction of homotyplc cell adhesion (%) of JS-136 T cells and NL-3 NK cells after stimulation with TPA, mAbs NKI-L16, anti-CD3 and anti-CD2r and with isotype-matched 
control antibodies directed against CD4 and the transferrin receptor (CD71). Stimuli were added in the following concentrations: TPA (10 ng mi-1), NKI-L1615 (1 jxg ml“ 1), anti-CD3 
antibodies25 (SPV-T3b; 10 (xgm r1), a combination of anti-CD2 antibodies17 (CLB-Tll.1/1 clone 6G4 and CLB- T ll.2 /1  clone 4B2; 10 fAgmP1), antl-CD4 (CLB-T4/1; ref. 26) and 
anti-CD71 (661G10; 10 f*g m l"1; ref, 27). Cell adhesion was blocked after addition of anti-LFA-1 antibodies19 (CLB LFA-1/1; 5 jxg ml-1) or anti-ICAM antibodies (RR 1/1; data not 
shown). Addition of anti-LFA-3 antibodies (TS2/9; S jxg m r1) did not inhibit cell adhesion. One representative experiment out of four performed is shown (s.d, <10%). All 
experiments were carried out in triplicate (s.d. <10%). JS-136 (CD2+ CD3'1' CD4+ LFA-1+ LFA-3* ICAM-1+) is a cytolytic T-cell clone, directed against HLA-DR28. The NK clone 
(NL-3) expressed the following surface molecules; CD3”  CD2+ LFA-1+ LFA-34' ICAM-1+. Cells were cultured as described previously28 and tested 4 days after re-stimulation 
when spontaneous cell aggregation was *£10%. Homotypic cell adhesion was measured as described previously15. Before the test, wells were washed twice in Iscove’s medium 
containing 10% FCS, resuspended, and 2 xio5 cells seeded in 96-well microtitre plates in a volume of 50 jxl. Monoclonal antibodies were added in a volume of 50 |xl and the 
cells were incubated for 40 min at 37 °C, after which aggregate formation was determined through light microscopy by at least two Investigators. Scores ranged from <1-100, 
in a scale of 10, where <1  indicated that essentially no cells were aggregated In clusters and 10, 20, 40, 60, SO and 100 correspond with cell aggregations of <10%, <30%, 
<50%, <80%, >80% In compact clusters, and >90% large compact clusters, respectively. The percentage aggregation was determined by counting the number of free cells, 
using the equation: percentage of aggregation=100 x [ l- (n o .  free cells/no, input cells)]; no. of input cells = no. cells per ml in control tube containing only cells and medium; 
no. free cells= no. nonaggregated cells per ml from experimental tube.
leukocytes with other cell types by binding to their respective 
ligands. Defined ligands of LFA-1 are the intercellular adhesion 
molecule-1 (ICAM-1, CD54) 11 and -2 (ICAM-2)12. Leukocytes 
do not spontaneously aggregate; activation o f  PKC by phorbol 
esters, such as TPA (12-O-tetradecanoylphorbol-13-acetate), 
however, can induce LFA-1- and CR3-dependent 
adhesion4*13-14. An anti-LFA-1 monoclonal antibody (NKI-L16) 
or its Fab fragments, reactive with a unique epitope on the 
of-chain, is also capable of inducing LFA-1-dependent adhesion 
with kinetics strikingly similar to those seen with TPA15. These 
observations indicate that LFA-l-dependent adhesion requires 
a change of the conformation of LFA-1.
This prompted us to investigate whether the T-cell receptor- 
CD3 complex, responsible for recognition of antigen5, or CD2, 
which is believed to contribute to cell adhesion by binding to 
the LFA-3 molecule6' 8, can modulate LFA-1-mediated adhesion. 
The binding of ligands by these glycoproteins generates second 
messengers mediating the activation of PKC9-10. Assuming that 
PKC can activate LFA-1, triggering of the CD2 or T-cell recep- 
tor-CD3 pathways should therefore result in T-cell adhesion16. 
Anti-CD3 monoclonal antibodies (mAbs) or a combination of 
two anti-CD2 mAbs required for T-cell proliferation17, added 
in soluble form or bound to plastic, indeed strongly enhanced 
homotypic aggregation of cells of an alloreactive human T-cell 
clone» JS-136 (Fig. 1; Table 1). Furthermore, anti-CD2 but not 
anti-CD3 mAbs promoted homotypic adhesion of CD3-  NK 
clone (NL-3) cells, whereas TPA or NKI-L16 induced adhesion 
of both CD3* and CD3“ cells, without an apparent increase in 
expression of LFA-1 or ICAM-1. Isotype-matched control anti­
bodies directed against other surface molecules expressed by 
these clones were ineffective at inducing adhesion, indicating 
that the adhesion induced by anti-CD3 or anti-CD2 mAbs is 
not caused by agglutination. The induced adhesion is mediated 
by LFA-1 because it can be inhibited by anti-LFA-1 antibodies, 
but not by anti-LFA-3 antibodies. This notion is supported by 
the characteristic Mg2+ dependence and temperature depen­
dence of LFA-1-mediated adhesion (data not shown).
The kinetics of aggregation were examined next (Fig. 2). 
Maximal aggregation of JS-136 cells was found within 20 min, 
regardless of whether the cells were stimulated with TPA, NKI- 
L16 or mAbs antirCD3 or anti-CD2. To measure the time course 
of LFA-1 activation, aggregates were disrupted at various time- 
points after initiation of adhesion, and the ability of the 
suspended cells to re-form aggregates was determined. Cells 
stimulated by TPA, NKI-L16 and mAb anti-CD2 were able to
re-aggregate without extra addition of stimuli, and remained 
maximally aggregated for >12  h. By contrast, the anti-CD3- 
induced aggregates were unable to re-form aggregates when the 
cells were resuspended later than 30 min after initial induction 
(Fig. 2), indicating that anti-CD3 mAb transiently activates
Time (min) Time (min)
FIG. 2 Kinetics of homotypic cell adhesion of T-cell clone JS-136 (%) induced 
by TPA, or mAbs NKI-L16, anti-CD2 or anti-CD3. Cel! adhesion was followed 
in time (—O— ) and the capacity of cells to re-aggregate after disruption 
of cell clusters (—• —) is shown. Cells were stimulated for various periods 
of time. Subsequently, aggregates were disrupted, and the % aggregation 
was determined after an additional incubation period of 40 min without extra 
addition of stimuli (—• —). The inability of anti-CD3-treated cells to re­
aggregate could be completely restored by the addition (arrow) of NKI-L16 
antibody ( - - - • —).
METHODS. Homotypic cell adhesion of cytotoxic T-lymphocyte clone JS-136 
cells was performed as described in Table 1. The percentage of aggregated 
cells was determined in the course of time, and the concentrations of mAbs 
used (—O—) are given in Tables 1 and 2. Activation of LFA-1 was measured 
at various time intervals (—• —). Cell clusters were disrupted by vigorous 
pipetting to form single-cell suspensions. Subsequently the capacity of cells 
to re-aggregate was measured without the addition of extra stimuli (experi­
ments were carried out in triplicate (s.d. < 10%; one representative experi­
ment out of four performed is shown, s.d. 10%). Nonspecific aggregation 
(spontaneous aggregation and aggregation induced by control antibodies of 
IgGl and lgG2a isotype) was always <10%.
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TABLE 2 Heterotypic cell adhesion of LFA-1 with LFA-1+ T-cell clones
T-cell clones Heterotypic
LFA-1 ~ LAD 6 LFA-1 JS-136 aggregation
pretreatment pretreatment Stimulus (%)
--- --- --- 10
--- --- NKI-L16 70
--- --- TPA 40
--- --- Anti-CD3 40
--- --- Anti-CD2 50
NKI-L16 — —• <1
TPA --- --- <1
Anti-CD3 --- — <1
Anti-CD2 --- --- <1
--- NKI-L16 --- 60
--- TPA --- 40
--- Anti-CD3 — 40
--- Anti-CD2 --- 40
Heterotypic cell adhesion of cloned LFA-1“ T cells (LAD 6) with LFA~1+ T cells 
(JS-136). Heterotypic cell adhesion was determined 90 min after addition of medium, 
NK1-L16 (1 fxg ml*1), TPA (10 ng m l"1), anti-CD3 (SPV-T3i>; 10 {Agrnl“ 1) and anti-CD2 
( T i l l  +T112, 10 juug m l'1). Pre-incubation of LAD 6 with NKI-L16, TPA, mAbs Anti-CD3 
or anti-CD2 did not result In the formation of cell clusters, whereas pre-incubation of 
JS>136 cells caused formation of heterotypic aggregates indicating that adhesion is 
induced through LFA-1. TPA, or mAbs NKI-L16, anti-CD3 or anti-CD2 did not induce 
homotypic aggregation of LAD 6 cells (data not shown). A representative experiment 
out of three is shown (s.d.<10%); experiments were carried out in triplicate (s.d.< 
10%). The LFA-1" T cell clone LAD 6 (CD2+ CD31 CD4+ CD8~ LFA-3+ ICAM+) was 
raised by limiting dilution of peripheral blood lymphocytes (PBL) from a LAD patient, 
Clones were grown weekly on stimulation with irradiated allogeneic PBL and ceils of 
the B-cell line JY, supplemented with phytohaemagglutinin (PHA; 0.2 jxg ml“ 1) and 
interleukin 2 (IL-2; 100 U ml-1). Heterotypic cell adhesion was determined by means 
of double fluorescence. LAD 6 cells (1 x lO 6 ml-1 were stained with red hydroethidine 
(HE; Polyscience, in yv/V-dimethylacetonfde) at a concentration of 3 mg ml-1 in Iscove's 
medium. JS-136 celis (1 x 106 m i"1) were stained with the green dye (sulphofluorescein 
diacetate (SFDA) in dimethyl sulphoxide; Molecular Probe) at a concentration of 
5 |xg m r \  After 1 h incubation at 37 °C, cells were washed twice with Iscove's medium 
containing 10% FCS and seeded in flat-bottomed plates in a concentration of 1 x lO 5 
HE-labelled cells together with 1 x lO 5 SFDA-iabelled cells per well. Aggregation was 
performed at 37 °C, and after 90 min the cells were fixed in 0,5% paraformaldehyde 
followed by fluorescence microscope analysis to determine the percentage of 
heterotypic cell aggregates. The aggregates were checked to be composed of equal 
ratio of the two different cell types. In those cases where LAD 6 cells or JS-136 cells 
were pretreated with NKI-L16, TPA, mAbs anti-CD2 or anti-CD3 for 20 min at 37 °C, 
the cells were extensively washed to remove nonbound antibodies.
LFA-1, and that CD2 and CD3 could activate LFA -1 through 
different signalling pathways. The transient CD3-mediated 
response was not due to decreased expression o f  LFA-1 or its 
ligand(s)5 because these anti-CD3-treated cells could still be 
induced to aggregate by NKI-L16 antibodies (Fig. 2). When, 
instead of activated T cells, resting peripheral blood lymphocytes 
were used, a maximal aggregation was only observed after 6 h 
incubation. This seems to be directly correlated with the 
expression of the NK1-L16 epitope on the LFA -1 molecule 
(Y.v.K., unpublished results).
To prove that induction of adhesion is a consequence of 
activation of the LFA-1 molecule, rather than activation of its 
ligand(s) or other adhesion molecules (CD2-LFA-3), we per­
formed heterotypic cell-binding studies with LFA-1-positive 
(LFA-1+) and LFA-l-deficient (LFA4~) T  cells of a patient 
suffering from leukocyte adhesion deficiency syndrome1,2,18. 
Leukocytes from these patients lack cell-surface expression of 
all C D 11 and CD18 molecules, generally owing to a genetic 
defect in the common /3-chain gene. AT-cell clone derived from 
this ‘severe-type’ leukocyte adhesion deficient patient com­
pletely lacked /3-chain messenger RNA expression and LFA-1, 
C R 3 and p l5 0 ,95 surface expression. But T  cells expressed 
normal levels of ICAM-1, CD2, CD3 and LFA-3 (data not 
shown). LFA-1“ cells could not be induced to adhere among 
themselves, but were able to bind to JS-136 (CD3+ LFA-1+) 
cells after addition of TPA, or mAbs NKI-L16, anti-CD3 or 
anti~CD2 (Table 2). When the LFA-1“ cells were incubated with 
the different stimuli, before mixing with the LFA-1+ cells, neither 
homotypic (among LFA-1“ or LFA-1+ cells) nor heterotypic 
adhesion was observed. By contrast, pre-incubation o f  the LFA-
1+ cells with the same stimuli resulted in the formation of large 
clusters of cells containing both LFA-1+ and LFA-1“ cells in a 
ratio of 1:1 (Table 2). These results show that T-cell adhesion 
is induced by activation o f LFA -1 and not by activation of its 
ligands. Induction of heterotypic T-cell adhesion by these stimuli 
exclusively activates the LFA-l-mediated adhesion pathway and 
not the CD2-LFA-3 adhesion pathway, despite the fact that the 
LFA-1“ T cells express normal levels of LFA-3 and CD2.
Evidence is thus presented for the existence o f an activated 
form of LFA-1. Binding o f NKI-L16 to LFA-1, or stimulation 
of PKC by TPA, or mAbs anti-CD2 or anti-CD3, probably 
results in a conformational modification of the LFA-1 molecule, 
leading to high-affinity ligand binding. Although induction of 
adhesion by NKI-L16 is thought to be exclusively an extracel­
lular event, the molecular alteration induced by the other stimuli 
would be catalysed by PKC. This notion is supported by the 
observation that PKC inhibitors completely block TPA- or anti- 
CD3-induced aggregation, but have no effect on induction of 
adhesion by NKI-L16 (Y.v.K. et a i , unpublished results). 
Alternatively, LFA -1 itself could be involved in signal trans­
duction19.
We propose that numerous LFA-1-dependent T-lymphocyte 
interactions occurring in an immune response are controlled by 
the T-cell preceptor-CD3 complex and by CD2. A case in point 
is the interaction between cytotoxic T lymphocytes and their 
target cells. It has been reported that LFA-1-dependent binding 
o f the effector T  cell to the target cell precedes recognition by 
the T-cell receptor-CD3 complex20. The results presented here 
indicate that this cell—cell interaction, although o f  low affinity, 
facilitates antigen recognition by the T-cell receptor-CD3 com­
plex, On antigen recognition, PKC, activated through CD3, 
could activate LFA -1 by direct phosphorylation o f  the /3-chain 
of LFA-121,22, or alternatively, by phosphorylation of a cytoske- 
letal protein such as talin , which then might bind and activate 
LFA-1. This strengthens the interaction between cytotoxic lym­
phocytes and target cells for efficient delivery of cytotoxic 
mediators causing target-cell lysis. Target-cell detachment could 
also be controlled by PKC. Phosphorylation and subsequent 
modulation of CD324 possibly results in downregulation of PKC, 
and could thus explain the inactivation of LFA -1 observed 
20 min after triggering with anti-CD3 antibody. □
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